Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Profit After Tax: 2022-2024

Historic Profit After Tax for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to -$95.5 million.

  • Day One Biopharmaceuticals' Profit After Tax fell 153.26% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.8 million, marking a year-over-year decrease of 80.04%. This contributed to the annual value of -$95.5 million for FY2024, which is 49.45% up from last year.
  • According to the latest figures from FY2024, Day One Biopharmaceuticals' Profit After Tax is -$95.5 million, which was up 49.45% from -$188.9 million recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Profit After Tax ranged from a high of -$95.5 million in FY2024 and a low of -$188.9 million during FY2023.
  • Its 3-year average for Profit After Tax is -$142.2 million, with a median of -$142.2 million in 2022.
  • In the last 5 years, Day One Biopharmaceuticals' Profit After Tax plummeted by 32.87% in 2023 and then surged by 49.45% in 2024.
  • Yearly analysis of 3 years shows Day One Biopharmaceuticals' Profit After Tax stood at -$142.2 million in 2022, then crashed by 32.87% to -$188.9 million in 2023, then spiked by 49.45% to -$95.5 million in 2024.